Dicerna Pharmaceuticals Inc (DRNA) Return on Assets ROA from the third quarter of 2021 to third quarter of 2020 and for the year 2021, Average High and Low, Fundamental Ratios from Sep 30 2021 to Sep 30 2020 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Dicerna Pharmaceuticals Inc   (NASDAQ: DRNA)


Dicerna Pharmaceuticals Inc 's ROA from the third quarter of 2021 to the third quarter of 2020 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Dicerna Pharmaceuticals Inc 's ROA in the third quarter of 2021?
Dicerna Pharmaceuticals Inc recorded a cumulative net loss of $-124 million during 12 months ending in the third quarter of 2021, resulting in a negative return on assets (ROA) of -18.17%.

However, within the Healthcare sector 360 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2021 quarter, so far to 3749, from total ROA ranking in the second quarter of 2021 at 3820.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter
Y / Y Total Assets Change 6.99 % 8.61 % -19.73 % 14.1 % 94.75 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -124 -129 -120 -113 -116
Return On Assets (TTM) -18.17 % -19.19 % -18.27 % -16.19 % -17.12 %
DRNA's Total Ranking # 3749 # 3820 # 3689 # 4003 # 3563
Total Assets (TTM) in million 701 765 625 648 655
Seq. Total Assets Change -8.43 % 22.39 % -3.58 % -1 % -7.04 %
Seq. Net Income Change - - - - -

DRNA's 5 Years Annual ROA >> Back to DRNA Management Effectiveness >> Compare DRNA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 115
Sector # 361
Overall # 3646

Return On Assets Statistics
High Average Low
-15.55 %
-49.99 %
-101.8 %
(Dec 31 2020)   (Mar 31 2017)





Financial Statements
Dicerna Pharmaceuticals Inc 's Assets $ 701 million DRNA's Balance sheet
Dicerna Pharmaceuticals Inc 's Income $ -17 million Quarterly DRNA's Income Statement
DRNA's Income by Division See DRNA's Income by Division



Annual Return On Assets (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018		 (Dec 31 2017)
FY 2017		 (Dec 31 2016)
FY 2016
Y / Y Total Assets Change 8.52 % 46.05 % 238.37 % 135.86 % -48.76 %
Total Assets in million 648 597 409 121 51
Y / Y Net Income Change - - - - -
Net Income in million -113 -120 -89 -64 -60
Annual Return On Assets -17.39 % -20.16 % -21.72 % -52.85 % -116.12 %

DRNA's 5 Years Annual ROA >> Back to DRNA Management Effectiveness >> Compare DRNA ROA to its Competitors



More Return On Assets Ratios
DRNA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DRNA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DRNA's Competitors
Subscribers only: Roa for Dicerna Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for DRNA's Customers

You may also want to know
DRNA's Roi DRNA's Inventory Turnover Ratio DRNA's Growth Rates DRNA's Dividend Comparisons
DRNA's Profitability Ratios DRNA's Asset Turnover Ratio DRNA's Dividend Growth
DRNA's Roe DRNA's Valuation Ratios DRNA's Financial Strength Ratios DRNA's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2021, within Healthcare Sector ROA

Date modified: 2026-09-26T07:08:33+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.